Bhutan vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Bhutan
100.0%
in 2024
Mus
100.0%
in 2024
Bhutan rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Bhutan
- Mus
How they compare
Bhutan currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 3 times across 14 shared years of data; in 2008 it was Bhutan ahead.
Bhutan ranks 1st and Mus ranks 1st of 144 countries.
Bhutan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bhutan | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 60.5% | 39.5% | Bhutan |
| 2010s | 92.9% | 90.7% | 2.1% | Bhutan |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Bhutan or Mus?
- Bhutan, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Bhutan and Mus?
- 0.0%, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Mus?
- 14 years are reported by both, from 2008 to 2024.
- How do Bhutan and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Bhutan ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.